With over a decade as executive director of the Pharmaceutical Chamber of ANDI (The Colombian National Business Association), Rodrigo Arcila Gomez, shares his optimistic insights on the growth of the sector, the current status of pricing negotiations, his key achievements, and the need for a pharmaceutical landscape built on trust.
Mr. Arcila, from our last interview in 2013, you concluded with the sentiment that the priority for the Colombian pharmaceutical sector should be on proper allocation of resources and establishing good pricing policies. What have been the major changes in these contexts for the sector in the last four years?
"As the Director of the Pharmaceutical Chamber, the main message I’m conveying to the government is that they need to minimize changes in the regulations in order to produce a balanced and steady environment."
